How to Value a Veterinary Telemedicine Platform in 2026

Veterinary telemedicine barely existed as a category five years ago. Today, platforms like Vetster, Dutch, and Airvet have raised hundreds of millions in venture capital, and a new wave of smaller, niche vet telehealth companies is hitting the market. I've been tracking this space closely because it sits at the intersection of two hot M&A verticals — veterinary services and healthcare technology — and the valuation dynamics are genuinely different from either one.

Vet telemedicine platforms typically trade at 2-6x revenue, putting them squarely in SaaS-adjacent territory. But calling them SaaS businesses oversimplifies the picture. The licensing complexity, the veterinary-client-patient relationship (VCPR) requirements, and the unique consumer behavior patterns create a valuation framework that deserves its own analysis.

Why Revenue Multiples, Not Earnings

Most vet telemedicine platforms are valued on revenue rather than SDE or EBITDA. The reason is the same as with SaaS businesses: these are growth-stage technology companies where the addressable market is large, margins should improve with scale, and buyers are paying for future economics rather than current profitability.

The U.S. pet care market exceeds $150 billion annually, and veterinary services represent roughly $38 billion of that. Telemedicine penetration is still in the low single digits. Buyers look at that gap and see a long runway, which is why revenue growth rate is the single most important valuation driver. A platform growing 80%+ year-over-year will trade at 5-6x revenue. One growing 20% will struggle to get 2x. The growth premium is that stark.

The Metrics That Matter

When I evaluate a vet telemedicine platform, I focus on five core metrics that tell me whether the business has real traction or just a slick app.

Monthly active consultations (MAC)is the primary indicator of platform health. Not registered users, not app downloads — actual completed consultations where a pet owner connected with a veterinarian and received clinical guidance. A platform doing 5,000+ monthly consultations has real traction. Under 1,000, and you're still in the proving-concept phase. Growth in MAC month-over-month tells you whether the product has found market fit.

Veterinary provider count and utilizationdetermines capacity and supply-side health. A platform with 200 licensed veterinarians doing an average of 25 consultations per month each is in a very different position than one with 50 vets doing 5 each. Provider utilization rate signals whether the platform has enough demand to retain its supply side. If vets aren't getting enough consultations to justify their time on the platform, they leave — and supply-side churn is the silent killer in marketplace businesses.

Consultation completion rate measures product quality. If 30% of initiated consultations are abandoned or end without resolution, the user experience has problems. Best-in-class platforms maintain 85%+ completion rates. Anything below 70% raises red flags about the technology, the provider matching, or the overall service design.

Revenue per consultation tells you the monetization efficiency. Most platforms charge $30-$75 per consultation, with some offering subscription models at $15-$30/month for unlimited basic consultations. The subscription model trades lower per-unit revenue for higher lifetime value and predictability — and predictable revenue commands higher multiples.

Net revenue retention (NRR) is the metric sophisticated buyers obsess over. In a subscription model, NRR above 100% means existing customers are spending more over time (upgrades, additional pets, add-on services). NRR above 110% is excellent and supports premium multiples. Below 90% means the business has a churn problem that growth is papering over.

The VCPR Problem: State Licensing as a Moat

This is the single most misunderstood aspect of vet telemedicine valuation, and it's where most generalist investors get tripped up. The Veterinary-Client-Patient Relationship (VCPR) is the legal prerequisite for a veterinarian to diagnose, treat, or prescribe for an animal. Traditionally, VCPR required an in-person examination. During COVID, many states relaxed this to allow telemedicine-established VCPRs. But the regulatory landscape has been shifting back.

As of 2026, state regulations on telemedicine VCPR establishment vary dramatically. Some states allow full telemedicine VCPR establishment (the platform can function as a complete virtual clinic). Others require an initial in-person visit before telemedicine follow-ups. A few still effectively prohibit veterinary telemedicine for anything beyond triage and general advice.

This creates a fascinating valuation dynamic. A platform that has navigated the licensing requirements across 40+ states has built a genuine regulatory moat. The compliance infrastructure — state-by-state veterinary board relationships, licensing verification systems, scope-of-practice guardrails — is extremely difficult and time-consuming to replicate. I view multi-state regulatory clearance as one of the most valuable assets in a vet telemedicine acquisition.

Triage vs. Diagnosis: The Regulatory Line That Matters

Vet telemedicine platforms fall into two broad categories: triage platforms and diagnosis platforms. The distinction has massive implications for valuation because it determines the total addressable market and the regulatory risk profile.

Triage platformshelp pet owners determine whether they need to go to the emergency vet, schedule a regular appointment, or manage at home. These platforms operate in a regulatory gray area that most states tolerate — they're providing general guidance, not diagnosing or prescribing. The revenue per consultation is lower ($15-$30), but the regulatory risk is minimal. Think of these as the veterinary equivalent of a nurse hotline.

Diagnosis platforms enable veterinarians to examine (via video), diagnose, prescribe medications, and manage ongoing conditions remotely. These platforms generate higher revenue per consultation ($50-$75+) and support subscription models, but they face the full weight of state veterinary board regulation. The upside is significantly higher, but so is the compliance burden.

Buyers generally pay higher multiples for diagnosis-capable platforms because the market opportunity is larger and the recurring revenue potential is stronger. But they discount heavily if the platform has been aggressive with regulatory interpretation — an enforcement action from a state veterinary board can shut down a revenue stream overnight.

Post-COVID Consumer Behavior

The COVID-era pet adoption boom created a massive new cohort of pet owners whose first instinct when their dog has a problem is to Google it, then book a virtual consultation. This is a permanent behavioral shift, not a pandemic blip. Millennials and Gen Z pet owners — who now represent the majority of new pet parents — are digital-native consumers who expect telehealth as a baseline service.

The data supports this. Veterinary telemedicine consultations grew roughly 300% from 2020 to 2023, declined slightly as in-person care resumed, then resumed growth in 2024-2025 as the convenience factor cemented itself. Platforms that retained their post-COVID users (rather than seeing them churn back to in-person only) have demonstrated genuine product-market fit. Retention cohort data from 2022-2023 is the most valuable dataset in any vet telemedicine diligence process.

Who Buys Vet Telemedicine Platforms

The buyer landscape is evolving rapidly. Three categories dominate:

Veterinary consolidators(Mars/VCA, NVA, Pathway) view telemedicine as a patient acquisition channel and a way to extend their clinic network's reach. They pay 2-4x revenue and want the technology to integrate with their existing clinic operations. For them, the platform is a feature, not a standalone business.

Pet care platforms(Chewy, Petco, Rover) see telemedicine as an extension of their ecosystem. Chewy's push into vet services via Connect with a Vet is the template — use telehealth to deepen the customer relationship and drive pharmacy and product revenue. These buyers pay 3-5x revenue and value the customer base and data as much as the technology.

Health tech acquirersview vet telemedicine as an adjacent market opportunity. Human telehealth companies that have built the technology infrastructure see veterinary as a lower-regulation, high-growth expansion. These buyers tend to pay the highest multiples (4-6x) because they're valuing the market position and growth trajectory rather than current financials.

What Kills Value in Vet Telemedicine

Regulatory concentration. If 60%+ of your consultations come from states where VCPR rules could tighten, your revenue base is fragile. Diversification across regulatory environments is essential.

Provider dependency. If your top 10 veterinarians handle 50%+ of consultations, you have a concentration problem. The platform should be bigger than any individual provider.

No path to profitability. Growth is great, but a platform burning $500K/month with no clear path to contribution margin positive will get punished in this market. Post-2023, buyers expect a credible unit economics story — not just a growth chart that goes up and to the right.

Thin technology moat. If the platform is essentially a video call scheduler with a payment processor, the technology is commoditized. Buyers pay premium multiples for platforms with proprietary triage algorithms, integrated medical records, pharmacy fulfillment, and AI-assisted diagnostic tools.

The Bottom Line

Veterinary telemedicine is a real category with real transaction activity, but it demands a nuanced valuation approach. The revenue multiple framework from SaaS applies directionally, but the state-by-state regulatory overlay, the marketplace dynamics between providers and pet owners, and the evolving VCPR landscape all introduce variables that generic tech valuation models miss. The platforms that will command premium exits are those with multi-state licensing infrastructure, strong provider networks, proven retention, and a clear position in the triage-to-diagnosis spectrum.